Polyspecific organic cation transporters and their biomedical relevance in kidney

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 5, 2013, Pages 533-538

  Koepsell, Hermann ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

nephrotoxicity; organic cation transporters; proton cation antiporters; renal cation transport; renal drug drug interaction

Indexed keywords

ANTIINFECTIVE AGENT; CARNITINE; CREATININE; DEBRISOQUINE; DESIPRAMINE; FLUOXETINE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; IMATINIB; INDINAVIR; LAMOTRIGINE; LEVOMEPROMAZINE; MAPROTILINE; METFORMIN; MITOXANTRONE; NISOXETINE; ONDANSETRON; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PAROXETINE; RHODAMINE 123; RITONAVIR; SPIPERONE; TRIMIPRAMINE; TROPISETRON;

CATION TRANSPORT; CELL MEMBRANE; CONFORMATIONAL TRANSITION; CREATININE CLEARANCE; DISULFIDE BOND; GENETIC VARIABILITY; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE EXCRETION; MYELOID LEUKEMIA; NONHUMAN; NUCLEOTIDE BINDING SITE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW;

EID: 84882450786     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328363ffaf     Document Type: Review

References (53)

1. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24:1227-1251.
2. Koepsell H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 2013; 34:413-435.
3. Motohashi H, Inui KI. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J 2013; 15:581-588.
4. Komatsu T, Hiasa M, Miyaji T, et al. Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter. Int J Biochem Cell Biol 2011; 43:913-918.
5. Koepsell H. Substrate recognition and translocation by polyspecific organic cation transporters. Biol Chem 2011; 392:95-101.
6. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs,MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2010; 201:105-167.
7. Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006; 319:879-886.
8. More SS, Li S, Yee SW, et al. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther 2010; 9:1058-1069.
9. Tamai I. Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm Drug Dispos 2013; 34:29-44.
10. Terada T, Inui K-I. Physiological and pharmacokinetic roles of H\+/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol 2008; 75:1689-1696.
11. Wittwer MB, Zur AA, Khuri N, et al. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem 2013; 56:781-795.
12. Keller T, Egenberger B, Gorboulev V, et al. The large extracellular loop of organic cation transporter 1 influences substrate affinity and is pivotal for oligomerization. J Biol Chem 2011; 286:37874-37886.
13. Brast S, Grabner A, Sucic S, et al. The cysteines of the extracellular loop are crucial for trafficking of human organic cation transporter 2 to the plasma membrane and are involved in oligomerization. FASEB J 2012; 26:976-986.
14. Schmitt BM, Gorbunov D, Schlachtbauer P, et al. Charge-to-substrate ratio during organic cation uptake by rat OCT2 is voltage dependent and altered by exchange of glutamate 448 with glutamine. Am J Physiol Renal Physiol 2009; 296:F709-F722.
15. Harper JN, Wright SH. Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. Am J Physiol Renal Physiol 2013; 304:F56-F67.
16. Choi MK, Song IS. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos 2012; 33:170-178.
17. Tzvetkov MV, Saadatmand AR, Bokelmann K, et al. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 2012; 12:22-29.
18. Egenberger B, Gorboulev V, Keller T, et al. A substrate binding hinge domain is critical for transport-related structural changes of organic cation transporter 1. J Biol Chem 2012; 287:31561-31573.
19. Pochini L, Scalise M, Galluccio M, et al. Reconstitution in liposomes of the functionally active human OCTN1 (SLC22A4) transporter overexpressed in Escherichia coli. Biochem J 2011; 439:227-233.
20. Pochini L, Scalise M, Galluccio M, Indiveri C. Regulation by physiological cations of acetylcholine transport mediated by human OCTN1 (SLC22A4). Implications in the nonneuronal cholinergic system. Life Sci 2012; 91:1013-1016.
21. Zhang X, Wright SH. MATE1 has an external COOH terminus, consistent with a 13-helix topology. Am J Physiol Renal Physiol 2009; 297:F263-F271.
22. Zhang X, He X, Baker J, Tama F, et al. Twelve transmembrane helices form the functional core of mammalian MATE1 (multidrug and toxin extruder 1) protein. J Biol Chem 2012; 287:27971-27982.
23. He X, Szewczyk P, Karyakin A, et al. Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 2010; 467:991-994.
24. Kido Y, Matsson P, Giacomini KM. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter. J Med Chem 2011; 54:4548-4558.
25. Jouan E, Le VM, Denizot C, et al. The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2. Fundam Clin Pharmacol 2012; www.ncbi.nih.gov/pubmed/22913740, doi: 10.111/j.1472-8206.2012.01071. [Accessed January 2013]
26. Ito S, Kusuhara H, Kumagai Y, et al. N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin Pharmacol Ther 2012; 92:635-641.
27. Dickens D, Owen A, Alfirevic A, et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol 2012; 83:805-814.
28. Saadatmand AR, Tadjerpisheh S, Brockmö ller J, Tzvetkov MV. The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol 2012; 83:1427-1434.
29. Song IS, Lee DY, Shin MH, et al. Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition. PLoS ONE 2012; 7:e36637.
30. Ishiguro N, Shimizu H, Kishimoto W, et al. Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos 2013; 41:149-158.
31. Haenisch B, Drescher E, Thiemer L, et al. Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3. Naunyn Schmiedebergs Arch Pharmacol 2012; 385:1017-1023.
32. Wang L, Giannoudis A, Austin G, Clark RE. Peroxisome proliferator- activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. Exp Hematol 2012; 40:811-819.
33. Choi JH, Yee SW, Ramirez AH, et al. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011; 90:674-684.
34. Gallegos TF, Martovetsky G, Kouznetsova V, et al. Organic anion and cation SLC22 'drug' transporter (Oat1, Oat3, and Oct1) regulation during development and maturation of the kidney proximal tubule. PLoS ONE 2012; 7:e40796.
35. Schaeffeler E, Hellerbrand C, Nies AT, et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 2011; 3:82.
36. Heise M, Lautem A, Knapstein J, et al. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 2012; 12:109.
37. Lin R, Li X, Li J, et al. Long-term cisplatin exposure promotes methylation of the OCT1 gene in human esophageal cancer cells. Dig Dis Sci 2013; 58:694-698.
38. Saito J, Hirota T, Kikunaga N, et al. Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: relationship to epigenetic variations in the 5'-upstream regulatory region. J Pharm Sci 2011; 100:3875-3883.
39. Asavapanumas N, Kittayaruksakul S, Meetam P, et al. Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPARalpha-independent pathways. Drug Metab Pharmacokinet 2012; 27: 513-519.
40. Hanafy S, El-Kadi AO, Jamali F. Effect of inflammation on molecular targets and drug transporters. J Pharm Pharm Sci 2012; 15:361-375.
41. Naud J, Michaud J, Beauchemin S, et al. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos 2011; 39:1363-1369.
42. Komazawa H, Yamaguchi H, Hidaka K, et al. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure. J Pharm Sci 2013; 102:1086-1094.
43. Urakami Y, Kimura N, Okuda M, Inui KI. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 2004; 21:976-981.
44. Tanihara Y, Masuda S, Sato T, et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H\+-organic cation antiporters. Biochem Pharmacol 2007; 74:359-371.
45. Imamura Y, Murayama N, Okudaira N, et al. Prediction of fluoroquinoloneinduced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther 2011; 89:81-88.
46. Ciarimboli G, Lancaster CS, Schlatter E, et al. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 2012; 18:1101-1108.
47. Reznichenko A, Sinkeler SJ, Snieder H, et al. SLC22A2 is associated with tubular creatinine secretion and bias of estimated GFR in renal transplantation. Physiol Genomics 2013; 18:201-209.
48. Stocker SL, Morrissey KM, Yee SW, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013; 93:186-194.
49. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86:299-306.
50. Kusuhara H, Ito S, Kumagai Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011; 89:837-844.
51. Yonezawa A, Inui KI. Organic cation transporter OCT/SLC22A and H\+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 2011; 81:563-568.
52. Iwata K, Aizawa K, Kamitsu S, et al. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol 2012; 16:843-851.
53. Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007; 74:477-487.